東大発新興、次世代遺伝子治療を開発へ　治験29年メド | AN Venture Partners

東大発新興、次世代遺伝子治療を開発へ　治験29年メド

MediaPortfolio Companies

東大発新興、次世代遺伝子治療を開発へ　治験29年メド

February 27, 2024

Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines

Press Release

Portfolio Companies

Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines

Cambridge, Mass., September 2, 2026

Crystalys Therapeutics Closes $130 Million Series B Funding to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

Press Release

Portfolio Companies

Crystalys Therapeutics Closes $130 Million Series B Funding to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

San Diego, July 23, 2026

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.

Privacy Policy

This website uses Google Analytics cookies for access analysis only. The collected data is used solely for improving the website and is handled appropriately. By clicking "AGREE", you consent to the use of cookies.